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Abstract
As an interface with the environment, the skin is a complex ecosystem colonized by many 
microorganisms that coexist in an established balance. The cutaneous microbiome inhibits 
colonization with pathogens, such as Staphylococcus aureus, and is a crucial component for 
function of the epidermal barrier. Moreover, crosstalk between commensals and the immune 
system is now recognized because microorganisms can modulate both innate and adaptive immune 
responses. Host-commensal interactions also have an effect on the developing immune system in 
infants and, subsequently, the occurrence of diseases, such as asthma and atopic dermatitis (AD). 
Later in life, the cutaneous microbiome contributes to the development and course of skin disease. 
Accordingly, in patients with AD, a decrease in microbiome diversity correlates with disease 
severity and increased colonization with pathogenic bacteria, such as S aureus. Early clinical 
studies suggest that topical application of commensal organisms (eg, Staphylococcus hominis or 
Roseomonas mucosa) reduces AD severity, which supports an important role for commensals in 
decreasing S aureus colonization in patients with AD. Advancing knowledge of the cutaneous 
microbiome and its function in modulating the course of skin disorders, such as AD, might result 
in novel therapeutic strategies.
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A multitude of microbiota inhabit our human epithelial surfaces. Although there is 
increasing evidence that these microbiota, which live in and on our bodies, are important to 
human health and disease, the many functions and consequences of these resident 
microbiota remain poorly understood. Given the challenges in being able to adequately 
culture all microbes present in a given sample, technological advances in genome 
sequencing have increased the ability to interrogate human epithelial microbiomes (the full 
collection of microbiota). Several technical advances in the study of the composition and 
function of the microbiome have collectively enlightened our understanding of the role of 
the microbiome in both pathogenesis of atopic dermatitis (AD) and in disease modification 
(Fig 1).1
Although animal models cannot fully recapitulate the human microbiome and disease states, 
the use of model organisms to deeply investigate host-microbial relationships has elucidated 
intriguing biological mechanisms. The continued integration of knowledge gleaned from 
patient-derived microbiota, animal models, and host-microbial interactions will be critical 
for developing and understanding therapeutic approaches. Prior publications have 
extensively reviewed the differences in the human skin microbiome based on various factors, 
including anatomic skin sites, sexual maturity, and skin physiology; this review provides a 
broad overview of the different aspects of microbiome, immunology, microbiology, and 
barrier research as related to AD, in particular early host-microbiome events in patients with 
AD. Here we review the role of the cutaneous microbiome in healthy and AD skin.
THE MICROBIOME OF NORMAL SURFACE EPITHELIA
The complexities of human microbial communities are reflected in the distinct microbiomes 
observed in the human skin, gut, and respiratory tract, among other body sites. Furthermore, 
the microbiota in distinct niches undergo changes over the human lifespan. The continual 
advances in our understanding of the human microbiome and its potential roles in human 
disease might subsequently lead to preventative and/or therapeutic strategies.
Skin microbiome research has highlighted the diversity and skin site specificity of microbial 
communities on human subjects, such that the different regional skin surfaces have different 
compositions of microbial communities.2–5 The skin hosts the most diverse commensal 
communities in the body, with more than 1000 different bacterial species from 19 different 
phyla.3,6 Although there are unique features of specific skin sites, some shared features of 
skin microbial communities reflect shared skin physiology: sebaceous skin sites often have 
Cutibacterium acnes (formerly known as Propionibacterium acnes). Small studies in healthy 
adult volunteers have shown that skin microbiomes are relatively stable for months to years 
and that each person might possess a personalized skin microbiome.7
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Studies have also demonstrated differences in the skin microbiomes of subjects at different 
life stages. For example, children who are less sexually mature have lower relative 
abundances of Corynebacterium and Cutibacterium species8 and greater diversity of skin 
fungi9 compared with more sexually mature subjects. The infant skin microbiome is a 
particularly active area of investigation because it might provide insights into early-life 
exposures.10–13 Children as young as 2 days old have site-specific differences in their skin 
microbiomes13 that might influence future development of disease.14,15
ESTABLISHMENT OF THE SKIN MICROBIOME IN EARLY LIFE
Early life is also characterized by rapid immunologic maturation. As such, it represents an 
active period during which host-commensal interactions can formatively affect how our 
immune system responds to our microbial brethren.16,17 Future success of microbially 
directed interventions to prevent or treat inflammatory skin disease will require a deeper 
understanding of the mechanisms responsible for development of a healthy symbiosis during 
this critical window.
Neonatal immune responses demonstrate a reduced propensity for activation or 
inflammation compared with those in adults. We now appreciate that this is not only due to 
immaturity of the immune system but also due to the existence of regulatory mechanisms 
unique to this early window. In infants, compared with older children or adults, activation of 
Toll-like receptors (TLRs), key sensors of the innate immune system, results in greater 
production of IL-6 and IL-23 and less production of TNF-α and IL-1.16 Composition and 
function of the adaptive immune system evolves in parallel, with regulatory T (Treg) cells 
found in greater abundance during fetal life and infancy.17–19 Although these differences 
place neonates at greater risk for disseminated infection, they also promote immune 
tolerance to self-antigens and foreign antigens, thereby preventing inflammation 
disadvantageous to healthy tissue development.
Birth marks an abrupt transition, with increased exposure to microbial products and 
antigens. Composition of microbial communities in infants are distinct from those seen later 
in life and can be influenced, at least initially, by exogenous factors, such as birth delivery 
mode and maternal commensals.10,12 Notably, the identity and function of these microbes 
can shape host health trajectory. In animal models early-life immune responses to gut- and 
lung-resident microbes have been shown to influence adult susceptibility to colitis, asthma, 
and anaphylaxis.20 In human infants the presence or absence of certain gut bacteria has been 
associated with increased proinflammatory metabolites and heightened risk of asthma.21 
Whether early disruption of the microbial community on skin directly affects future risk of 
inflammatory skin disease remains an open question. However, it is notable that recent 
longitudinal studies examining the skin microbiome in patients at risk for AD have found 
alterations in skin flora that predate disease onset.13,22
Until recently, little was known about the effect of early-life microbial exposures on skin 
immune function. Modeling this complex relationship in mice has taught us that these early-
life interactions are likely to be of equal or greater significance in skin as in other tissues. 
When neonatal mice are colonized by the commensal bacterium (coagulase-negative 
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Staphylococcus [CoNS]) Staphylococcus epidermidis, they develop a large percentage of 
Treg cells specific for S epidermidis and mount less inflammation to this microbe on 
rechallenge in later life. In contrast, delaying S epidermidis exposure until adulthood 
prevents this protective effect and promotes skin inflammation in responses to this otherwise 
“healthy” bacterium (Fig 2).22
At least 1 factor accounting for this age-dependent difference is the greater density of Treg 
cells found in neonatal compared with adult skin.23 Intriguingly, these Treg cells are 
markedly decreased in the skin of young mice raised under gnotobiotic (“germ-free”) 
conditions and in those lacking hair follicles, a major tissue niche for skin CoNS species. 
Indeed, colonization of hair follicles by commensal microbes appears to stimulate 
production by isthmus keratinocytes of a chemokine, CCL20, which then helps recruit these 
Treg cells into the skin (Fig 2, left panel).24
Thus animal models suggest that mechanisms promoting establishment of a healthy 
immunologic symbiosis with our skin microbiota are preferentially active early in life and 
can be facilitated by microbes themselves. Of course, there are notable differences between 
mice and human subjects with regard to timing of adaptive immune development, 
composition of skin bacterial communities, and skin structure. Thus how these findings 
translate to human biology and their implications for disrupting the composition of the 
neonatal skin microbiota will be a fruitful area of active investigation. Although detailed 
immunologic phenotyping of neonatal human skin has not yet been undertaken, Treg cells 
are enriched in pediatric compared with adult human skin.25
In considering potential translational applications of skin microbiome research, one can 
envision both corrective interventions to treat an established skin disease and preventative 
measures to reduce risk of disease onset or mitigate future severity. The latter might be 
especially relevant for conditions such as AD, in which variable penetrance based on genetic 
susceptibility and an early age of onset are defining features.26 Continued work to define the 
early-life influence of skin microbes on cutaneous immune function, both in the context of 
healthy and barrier-disrupted skin, will be critical to inform future development of 
prevention-oriented recommendations and microbe-based interventions.
IMMUNE-COMMENSAL CROSSTALK IN THE SKIN
The skin presents a physical barrier to harmful agents while establishing a unique innate 
immune system to regulate resident microbial communities. In contrast to other epithelial 
surfaces, such as the gut, which maintain physical separation from microbes through 
establishment of a mucous layer, the dense distribution of skin appendages creates a large 
surface area for close communication with microbes.27 The skin strictly regulates a 
sophisticated set of innate antimicrobial gene products that include antimicrobial peptides 
and proteins, lipids, a pH barrier, and free radical production to control the surface microbial 
community.28 A network of immune cells patrol the skin to reinforce the physical barrier 
because commensal and many potential pathogens can penetrate the epidermis after even a 
minor breach.29 The interplay between the epithelial barrier, immune defense, and the 
cutaneous microbiome has emerged as a key system for maintaining balance between health 
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and disease.30,31 Mounting clinical and experimental evidence suggests that modulating the 
microbiome might be efficacious for the treatment of inflammatory skin conditions.32 
However, the fundamental mechanisms underlying the immune-commensal crosstalk are 
only beginning to unfold. A nuanced understanding of the microbial factors that regulate 
skin immunity offers an opportunity to harness the power of the microbiome for therapeutic 
benefit.
Studies in germ-free mice have revealed that optimal immune cell function in healthy skin 
requires cues from indigenous microbes (Fig 2).33 For instance, the ability of effector T cells 
to make cytokines, such as IL-17A and IFN-γ, is dramatically abrogated in the absence of 
commensals. This defect is only restored with association of a skin commensal, S 
epidermidis, and not microbes residing in the intestine, highlighting the nonredundant role 
of skin-resident microbes in immune modulation.33,34 S epidermidis controls T-cell effector 
function by co-opting existing innate immune pathways, in this case IL-1α production from 
keratinocytes and dendritic cells. Although skin-derived innate signals are dispensable for 
the specification of T cells in the lymph node, these commensally induced molecules 
stimulate T cells on entry into the skin and sustain their effector functions. Importantly, this 
homeostatic tuning of skin T-cell function occurs in the absence of overt inflammation and 
in the context of an intact epidermal barrier.35
Several lines of evidence suggest that maintaining microbial diversity is advantageous to 
support the rich immune milieu of the skin. For instance, certain key microbes can elicit 
specific types of immune cells to the skin. Defined strains of S epidermidis induce IL-17A, 
producing CD8 (TC17) cells that reside in the epidermis.35 This cell population is actively 
generated on S epidermidis colonization through dendritic cell-dependent antigen 
presentation of bacterial N-formyl methionine peptides.36 In line with these experimental 
findings, human skin tropic T cells produce IL-17A and IFN-γ in response to stimulation 
with S epidermidis antigen.37 Moreover, TC17 cells are constitutively found in normal 
human skin33,38 and are enriched in squamous cell carcinomas39 and psoriatic plaques,40 
suggesting that commensally induced cells can contribute to skin disease. Indeed, the 
demonstration of increased TH17-driven gene expression in the skin of healthy pediatric 
control subjects and the significantly greater Th17-related gene expression in the lesional 
and nonlesional skin of infants with recent-onset AD potentially reflect this early period of 
response to environmental commensals.41,42
Specificity of commensal interactions with the host immune system is not limited to cognate 
T-cell responses. Indeed, the first detailed molecular description of the ability of commensal 
skin bacteria to benefit skin immunity came with the identification of chemical moieties 
displayed on commensals that interact with innate immune receptors to drive certain 
responses. A TLR2 ligand, lipoteichoic acid, from a commensal strain of S epidermidis and 
not pathogenic bacteria is uniquely able to dampen skin inflammation.43 S epidermidis can 
also enhance innate immune defense by enhancing antimicrobial peptide expression.44 
Several members of the commensal genus Corynebacterium have the cell envelope 
component mycolic acid, which can specifically induce IL-17A+ dermal γδ T cells (Fig 2).
45
 By contrast, CD4+ TH17 programs are broadly triggered by a wide array of microbes on 
skin colonization.35 Thus it is tempting to speculate that the cutaneous immune system has 
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evolved to sense skin microbial complexity and to use this information as a rheostat to 
continuously calibrate its function.
The myriad of immune cells elicited by commensals have several contextual roles in 
reinforcing the epidermal barrier. Commensal-specific immune responses help provide 
heterologous protection against dermal pathogens. By augmenting epidermal antimicrobial 
function, commensal-specific T cells limit the ability of pathogens, such as Candida 
albicans, to establish infections.35 Additionally, effector T cells in the skin use commensal 
signals as natural adjuvants to amplify ongoing immune responses to pathogens.33,46 Skin T 
cells also play a crucial role in monitoring microbes in the steady state. Recombination-
activating gene 1–deficient animals, which lack an adaptive immune system, have dramatic 
shifts in the composition of their skin microbial communities and bacterial translocation to 
skin lymph nodes.47 Patients with primary immunodeficiencies show similar alterations to 
commensal communities and a dramatic susceptibility to skin infections.48 Repair and 
regeneration are key features of inflammatory resolution. Commensal-specific TC17 cells 
aid in the healing process by promoting epidermal re-epithelialization.36 Thus one reason for 
maintaining such a rich milieu of microbes might be to maintain the complex repertoire of 
immune cell types and functions that aid not only in host defense but also in repair and 
regeneration of healthy skin.
The dynamic conversation between immune cells and commensals is disturbed when the 
skin barrier is compromised in patients with inflammatory diseases, such as AD, diabetic 
wounds, and skin infections.49,50 Such inflammatory reactions are often accompanied by a 
reduction in the complexity of microbial communities and outgrowth of pathogenic species, 
such as Staphylococcus aureus.51 If and how this reduction in microbial communities affects 
disease and whether pathogenic species expansion during inflammation causes disease or is 
merely a consequence is an area of active investigation. Untangling these observations and 
defining the microbial players that contribute to immune fitness will allow for the use of 
microbial interventions to manipulate immune responses and restore health.
S AUREUS AND AD
AD has a well-known association with altered skin microbiota, with a high prevalence of S 
aureus colonization and secondary infections that was recognized well before the application 
of DNA-sequencing approaches.52 Epidemiologic, metagenomic, and functional studies 
have since shown this complex host-pathogen relationship between S aureus and AD to be a 
sophisticated interaction between host and pathogen factors.53 Host factors include the 
hostile environment created by the physical, chemical, and antimicrobial properties of 
healthy skin, many of which are altered in AD skin. Pathogen-specific factors include highly 
evolved mechanisms facilitating adhesion, epidermal dissolution invasion, and 
proinflammatory mechanisms, which directly drive TH2, TH17, and innate immunity in the 
skin, promoting or exacerbating the inflammatory component of AD (Fig 3).53
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AD AND S AUREUS: EPIDEMIOLOGY
S aureus is commonly found on the skin of patients with AD,54–58 with reported rates of 
carriage varying from 30% to 100% depending on the type of patient, the sample size, and 
sampling and analysis methods, whereas in healthy control subjects the prevalence is about 
20%. A recent meta-analysis of 95 observational studies of culture-based methods reported 
that the prevalence of S aureus carriage by patients with AD was 70% on lesional skin 
compared with 39% on nonlesional skin or healthy control skin within the same patient.58 
The rate of S aureus colonization in this meta-analysis was related to disease severity.58 RT-
PCR studies estimating the density of S aureus on both lesional and nonlesional skin have 
shown correlation with disease severity,57 confirming results from earlier culture-based 
studies.54,55
Analysis of the skin microbiota by using deep shotgun metagenomic sequencing and 
sequencing 16S rRNA genes has shown a reduction of microbial diversity during an AD 
flare (Fig 1). Microbiome diversity decreased in inflamed atopic skin, with reductions in the 
genera Streptococcus, Corynebacterium, and Cutibacterium and the phylum Proteobacteria 
toward the genus Staphylococcus in general and S aureus in particular.14,50,59–61 Shotgun 
metagenomic sequencing showed that patients with AD are usually colonized with a single 
strain of S aureus during a severe flare.59 Microbiome composition reverted to more normal 
diverse communities during treatment and recovery.50
S aureus strains isolated from patients with AD show differences to those isolated from 
unaffected carriers; clonal complex (CC1) strains are enriched among patients with AD, 
whereas the CC30 strains most frequently isolated from nasal carriers in the healthy 
population are less common in patients with AD.62–64 Although evidence that S aureus is 
directly causative of AD is lacking, there is abundant evidence that this bacterial species is 
highly influential in disease pathogenesis, is associated with severe disease flares, and 
significantly influences the disease phenotype. The mechanisms through which S aureus 
influences AD are beginning to be understood, as are the critical and dynamic relationships 
between S aureus and the microbiome, especially non–S aureus staphylococci. Here we 
briefly review mechanisms of adherence and colonization and mechanisms causing barrier 
destruction and S aureus–driven activation of inflammation.
MECHANISMS OF ADHERENCE AND COLONIZATION IN AD SKIN
S aureus has developed multiple mechanisms to gain purchase on the hostile and difficult 
environment presented by healthy and intact human skin (Fig 3). In contrast to healthy skin, 
AD skin is permissive for S aureus colonization. The antimicrobial peptides LL-37, β-
defensins, and dermicidin are present at reduced levels in AD skin. One mechanism 
underlying this effect is the known inhibition of IL-4 and IL-13 on human β-defensin 2 and 
3 gene expression.65 S aureus species grow poorly in acidic conditions, as seen in healthy 
stratum corneum, but grow much better in higher pH conditions, which are often seen in 
patients with AD.66 S aureus isolated from patients with AD binds more strongly to intact 
AD skin67 and in standard binding assays than S aureus isolated from unaffected carriers,62 
an effect that is modulated by levels of filaggrin breakdown products (natural moisturizing 
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factor) in human corneocytes.68 In patients with established AD, filaggrin deficiency, either 
genetic or acquired from TH2 skewing, leads to irregular or deformed corneocytes.69 S 
aureus isolates from patients with AD also bind more strongly to these corneocytes 
compared with isolates from unaffected control subjects in a clumping factor B-dependent 
fashion.62
DESTRUCTION OF THE EPIDERMAL BARRIER AND PROINFLAMMATORY S 
AUREUS MECHANISMS
In addition to having excellent adhesion and immune avoidance mechanisms, S aureus has 
well-developed resources to penetrate and disrupt the skin barrier (Fig 3). S aureus a-toxin is 
a cytotoxin secreted as a water-soluble monomer, which forms a heptameric β-barrel pore in 
host cell membranes.70,71 In the epidermis it directly forms pores in keratinocytes, which 
erodes the integrity of the epidermal barrier. α-Toxin is critical to formation of the S aureus 
biofilm,72 which makes elimination of S aureus much more difficult to achieve. S aureus 
produces at least 10 proteases, a number of which facilitate dissolution of and penetration 
through the stratum corneum.73 Importantly, the activity of these proteases is enhanced in 
the absence of filaggrin and in the presence of canonical TH2 cytokines.73 In addition to 
secreted proteases, S aureus can directly stimulate endogenous keratinocyte proteases, 
including kallikrein (KLK) 6, KLK13, and KLK14, highlighting an additional mechanism 
toward barrier destruction.30 S aureus α-toxin modulates the skin host to viral infection.74 
These discoveries illustrate the complexity of interactions between host factors (TH2 
immunity, barrier deficiency, and reduced antimicrobial peptides) and pathogen-driven 
mechanisms.
S aureus expresses several molecules that contribute to disease pathogenesis through 
proinflammatory mechanisms (Fig 3). These include α-toxin, a pore-forming toxin that 
directly causes cellular damage in keratinocytes with a resultant effect on skin barrier 
function and possible effects on susceptibility to viral infection.75 When solubilized, The 
cell wall–bound protein A triggers inflammatory responses from keratinocytes through the 
TNF receptor. Staphylococcal superantigens, such as staphylococcal enterotoxin (SE) A, 
SEB, SEC, and toxic shock syndrome toxin 1, trigger B-cell expansion and cytokine release.
75
Proinflammatory staphylococcal lipoproteins induce thymic stromal lymphopoietin 
expression in primary human keratinocytes in a TLR2/TLR6-dependent manner, identifying 
another possible mechanism through which S aureus induces a Th2 response.76 Both 
mechanisms, barrier disruption and TH2 induction, make food allergy development more 
likely. S aureus incorporates short-chain unbranched fatty acids into its cytoplasmic 
membrane when growing in vivo.77 This increases membrane fluidity and could influence 
the expression of virulence factors78 and tolerance to host innate immunity, such as 
resistance to oxidative stress mediated by staphyloxanthin.78 Incorporation of skin fatty 
acids into bacterial lipoproteins increases their proinflammatory properties.79 S aureus 
secretes phenol-soluble modulins (PSMs), which are direct proinflammatory drivers with 
compartment-specific effects. In the epidermal compartment PSMa stimulates keratinocyte 
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production of IL-36 and IL-36α-driven γδ T cell–mediated inflammation, whereas in the 
dermal compartment it stimulates IL-1β–driven80 and innate lymphoid cell (ILC)–driven81 
TH17 inflammation. PSMγ (δ-toxin) also stimulates dermal mast cells and induces skin 
inflammation.82 S aureus mechanisms that contribute to AD pathogenesis have been 
comprehensively reviewed.53
CAN COMMENSAL ORGANISMS BE USED AS THERAPY FOR AD?
There are several lines of evidence suggesting that CoNS species could be therapeutically 
beneficial to AD. This approach is supported by birth cohort studies, which have shown that 
the presence of staphylococci, other than S aureus, at 2 months of age can protect infants 
against later development of AD.13,22
In addition, some CoNS species are able to fight against pathogens.83 Several previously 
unknown and potent anti–S aureus molecules have been discovered to be produced by skin 
CoNS species, such as S epidermidis, Staphylococcus hominis, and Staphylococcus 
lugdunensis.84–86 This anti–S aureus function of the commensal microbiome might be 
particularly useful in patients with AD because a high-throughput screen of CoNS species 
found that these antimicrobial strains are deficient on lesional and, to a lesser extent, 
nonlesional AD skin.85 Interestingly, these antimicrobials are only made by specific strains 
of CoNS species and were not initially predictable by using 16S sequencing. Also, because 
the antimicrobials produced by CoNS species synergize with the human antimicrobial 
peptide LL-37 and LL-37 is also relatively deficient in adult lesional AD skin,87 patients 
with chronic AD appear to have an exacerbated deficiency in innate antimicrobial defense 
against S aureus. Autoinducing peptide, which is produced by commensal organisms, can 
block S aureus accessory gene regulator–Quorum Sensing88 and therefore S aureus 
colonization and skin infection.89 S epidermidis has also been shown to suppress skin 
inflammation through TLR crosstalk.43 However, TLR ligands also exist in S aureus, so that 
the role of CoNS TLR ligands in reducing S aureus colonization is unclear.
In an attempt to address the deficiency of antimicrobial activity from the AD microbiome, a 
double-blind, placebo-controlled trial of CoNS species with antimicrobial activity was 
conducted. Results showed that topical application of antimicrobial CoNS bacteria was 
effective in mouse models of AD.85 CoNS species with anti–S aureus activity from patients 
with AD, which were far fewer than in healthy control subjects, were collected, expanded, 
applied to AD skin, and shown to reduce colonization by S aureus85; these studies are 
advancing to topical use of one lead strain of CoNS with anti–S aureus action (Fig 4). 
Furthermore, recent results from a similar 1-week trial have shown that this intervention can 
significantly improve local Eczema Area and Severity Index scores.90 Another recent open-
label trial that evaluated Roseomonas mucosa found that topical application of this gram-
negative organism decreased AD severity, pruritus, and the use of topical corticosteroids.91 
This observation mirrors other reports of anti-inflammatory effects from environmental 
bacteria92 but lacks a known mechanism of action.
Taken together, current preclinical and clinical trial results strongly support the use of 
commensal skin bacteria in the therapy of AD. However, these studies are still quite 
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preliminary, and the effect on the cutaneous microbiome and safety, including long-term 
safety, of topical application of commensal organisms that target S aureus is unknown.
In summary, there is growing evidence of the key role of the microbiome in the pathogenesis 
of AD, from both the predominance of S aureus and the relative reduction of commensal 
organisms, which might play a role in controlling S aureus growth. However, many 
questions remain, including the following: (1) What is the effect of antiseptics or 
administration of systemic AD treatment on the skin microbiome? (2) How does short-term 
treatment with antibiotics affect the AD microbiome, and are certain antibiotics more 
deleterious? (3) How does therapy, including topical therapy, conventional nonspecific 
immunomodulators, and novel targeted therapy, such as dupilumab, affect the microbiome? 
(4) Are changes in the neonatal gut microbiome a risk factor for AD development? 
Successful treatment of AD in the future through microbiome manipulation with topically 
applied commensals has the potential not only to advance our understanding about AD 
pathogenesis but also to greatly expand the spectrum of topical treatment options for AD. 
Vaccines against S aureus also represent a possible innovative approach to manipulate the 
AD microbiome.93
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FIG 1. 
An example of a pipeline for skin microbiome studies in patients with AD. The pipeline can 
begin by posing a scientific question, with subsequent recruitment of patients and control 
subjects, phenotyping of patients with AD, and collection of clinical samples (top left). 
Microbiota from clinical samples can either be directly sequenced to study the complex 
communities of microbiota (the microbiome) or first cultivated to investigate individual 
clinical isolates through whole-genome sequencing (and/or with model systems). Shotgun 
metagenomic sequencing refers to the sequencing of all genetic material in a complex 
sample and can provide information on bacteria, fungi, and viruses within the sample; the 
functional potential of the mixed microbial communities; and the different microbial strains. 
Sequencing both cultivated isolates (whole-genome sequencing) and the complex 
communities of microbes (shotgun metagenomics sequencing) can provide complementary 
information. The bioinformatics analyses of microbial sequencing data can identify the 
microbiome differences between patients with AD and healthy control subjects, which is 
graphically represented by bar charts that indicate the relative abundances of different 
staphylococci shown as different colors. The y-axis of bar charts represents 0% to 100% 
relative abundance. Differences in the microbiota found on patients versus control subjects 
can be studied in mouse models using clinically relevant isolates to examine microbial 
strain-level differences. For example, differences in host responses can be observed in the 
histology (lower panels) from mice who undergo application of different patient-associated 
staphylococcal strains (AD10.A30, USA300, HC.B1, AD04.E17)1 versus tryptic soy broth 
(TSB) control; comparisons can be made in epidermal thickening and immune cell infiltrates 
elicited by different strains. Further studies might provide insight into the role of the skin 
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microbiome in disease pathogenesis, which could lead to development of microbiome-
targeted therapeutics for patients.
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FIG 2. 
Age-dependent immune-commensal crosstalk in skin. Left panel, Some cutaneous immune 
cells, in particular CD4+ T cells generated in response to the commensal S epidermidis, are 
notably age dependent. Neonatal colonization by S epidermidis yields a population of 
antigen-specific CD4+ T cells dominated by Treg cells. In contrast, when exposure is 
delayed until adulthood, cytokine-producing effector CD4+ T cells predominate. Only early-
life exposure is conducive to the establishment of antigen-specific immune tolerance and 
protection against skin inflammation on subsequent exposure. One factor accounting for this 
age-dependent response is the high density of Treg cells found in neonatal skin, which 
conditions the skin for tolerogenic interactions with the microbiota through yet undefined 
mechanisms. Neonatal skin Treg cells are preferentially localized around hairfollicles, a 
dense niche for commensal skin microbes. Right panel, Colonization of adult skin with 
specific microbiota results in an IL-1–meditated homeostatic effector immune response, 
including TH1 and TH17 cells, as well as dermal IL-17A+ γδ T cells. Certain strains of S 
epidermidis also induce commensal-specific populations of IL-17A+CD8+ T cells (TC17) 
through CD103+ dendritic cells.
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FIG 3. 
S aureus has highly evolved multiple cell-wall proteins and secreted factors that enable 
adhesion to human skin and barrier disturbance by using physical, chemical, and 
inflammatory mechanisms. Adhesion, S aureus has developed several surface molecules to 
adhere to the human stratum corneum, including clumping factors A and B (ClfA and ClfB), 
fibronectin-binding protein (fnBP), and iron-regulated surface determinant A (IsdA). Barrier 
destruction, S aureus α-toxin, a water-soluble cytotoxin, forms a heptameric β-barrel pore in 
host cell membranes. In the epidermis it directlyforms pores in keratinocytes, which erodes 
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the integrity of the epidermal barrier. S aureus produces at least 10 proteases, a number of 
which facilitate dissolution of the stratum corneum. In addition to secreted proteases, S 
aureus can directly stimulate endogenous keratinocyte proteases, including KLK6, KLK13, 
and KLK14, highlighting an additional mechanism toward barrier destruction. 
Proinflammatory mechanisms, Cell-wall bound protein A, when solubilized, triggers 
inflammatory responses from keratinocytes through TNF receptor (TNFR). Staphylococcal 
superantigens, such as SEA, SEB, SEC, and toxic shock syndrome toxin-1 (TSST-1), trigger 
B-cell expansion and cytokine release. S aureus secretes PSMs, which are direct 
proinflammatory drivers with compartment-specific effects. In the epidermal compartment 
PSMs stimulate IL-36α-driven γδ T cell–mediated inflammation, whereasinthe dermal 
compartmentthey stimulate IL-1β-driven TH17 inflammation.
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FIG 4. 
Potential role of biotherapy in patients with AD. Biotherapy for AD takes advantage of the 
natural antipathogen properties of human CoNS species. A, As a first step, microbes are 
grown out from swabs of an affected subject, with the most biologically active strains then 
selected for expansion. This generates the lead ideal strain, which is trialed back on the 
donor subject and compared with a randomized placebo vehicle. B, Ifsuccessful atthis 
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stage,the lead strain istrialed in a largercohortof affected subjects. C, Finally, the strain is 
applied to high-risk children as a preventative measure.
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